22260-51-1

• 常用中文名：甲磺酸溴隐亭
• 常用英文名：CB-154 mesylate
• CAS号：22260-51-1
• 分子式：C₃₃H₄₄BrN₅O₈S
• 分子量：750.700
• 相关类别： 原料药 神经系统用药 抗震颤麻痹药
• 发布时间：2018-06-16 09:36:36
• 更新时间：2026-07-02 00:59:52
• Bromocriptine mesylate 是一种有效的多巴胺 D2/D3 受体激动剂，结合多巴胺 D2 受体，pK_i 为 8.05±0.2。

名称

• 中文名: 甲磺酸溴隐亭
• 英文名: bromocriptine methanesulfonate
• 中文别名: 溴麦角环肽甲磺酸盐; 2-溴-alpha-麦角环肽甲磺酸盐; 甲磺酸溴隐亭/甲磺酸溴麦角环肽; 甲磺酸溴隐亭/甲黄酸溴麦角环肽; 甲磺酸溴隐亭,10 MM DMSO 溶液; 2-溴-Α-麦角隐亭甲磺酸盐; (6,9R)-5-溴-N-((2R,5S,10AS,10BS)-10B-羟基-5-异丁基-2-异丙基-3,6-二氧八氢-2H-恶唑[3,2-A]吡咯并[2,1-C]吡嗪-2-基)-7-甲基-4,6,6A,7,8,9-六氢吲哚并[4,3-FG]喹啉-9-甲酰胺甲磺酸盐; BROMOCRIPTINE MESYLATE,D2-LIKE DOPAMINE RECTOR激动剂; 甲磺酸溴隐亭 标准品; 2-溴Α-麦角隐碱甲磺酸盐; 甲黄酸溴麦角环肽; 甲磺酸溴麦角环肽; 溴隐亭甲磺酸盐; 甲磺酸溴隐亭系统适用性 标准品
• 英文别名: TIANFU-CHEM CAS NO.22-1 Bromocriptine mesylate; 2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYL-PROPYL)ERGOTAMAN-3',6',18-TRIONE-METHANESULFONATE; Ergocryptine, 2-bromo-, monomethanesulfonate (salt) (8CI); Bromocriptine (mesylate); 2-Bromine-a-ergocryptine Methanesulfonate; Parlodel; (+)-BROMOCRIPTINE METHANESULFONATE; Bromocriptine mesylate - Bio-X; Bromocriptine mesylate; (+)-Bromocriptine methanesulfonate salt, Bromocriptine mesylate salt, (+)-2-Bromo-12μ-hydroxy-2μ-(1-methylethyl)-5μ-(2-methylpropyl)ergotaman-3μ,6μ-18-trione methanesulfonate salt; Bromocriptine mesylate, D2-like dopamine rector agonist; (+)-Bromocriptine methanesulfonate salt; EINECS 244-881-1; Bromocriptine mesilate for system suitability CRS; (5'alpha)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6', 18-trione mesylate; 2-bromo-alpha-ergocryptinmethanesulfonate; (5'α)-2-Bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate (1:1); Bromocriptine mesyla; Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)-, monomethanesulfonate (salt) (9CI); (6aR,9R)-5-bromo-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg; 2-Bromo-α-ergocryptine methanesulfonate salt,(+)-2-Bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)ergotaman-3′,6′-18-trione methanesulfonate salt, (+)-Bromocriptine methanesulfonate salt, Bro; 8,9-hexahydroindolo[4,3-fg]quinoléine-9-carboxamide (1:1); 2-bromo-α-ergocryptine methanesulfonate salt; (6aR,9R)-5-bromo-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate (salt); bromocriptinemesilate; acide méthanesulfonique - (6aR,9R)-5-bromo-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-méthyléthyl)-5-(2-méthylpropyl)-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-méthyl-4,6,6a,7,; Apo-Bromocriptine; 2-BROMO-ALPHA-ERGOCRYPTINE METHANESULFONATE SALT; (5'α)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman methanesulfonate (1:1); hydroindolo[4,3-fg]chinolin-9-carboxamid(1:1); acide méthanesulfonique - (6aR,9R)-5-bromo-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-méthyléthyl)-5-(2-méthylpropyl)-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-méthyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoléine-9-carboxamide (1:1); (5'A)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)ERGOTAMAN-3',6',18-TRIONE MESYLATE; Bromocriptine mesylate //BP; (+)-BROMOCRIPTINE MESYLATE; (5'α)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman methanesulfonate (salt); Bromocriptine mesilate; Pravidel; (5'α)-2-BroMo-12'-hydroxy-2'-(1-Methylethyl)-5'-(2-Methylpropyl)ergotaMan-3',6',18-trione Methanesulfonate; High Quality Bromocriptine Mesylate Powder CAS22-1; Bromocriptin mesylate; 2-bromo-12'-hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione monomethanesulphonate; cb-154; BROMOCRIPTINEMESYLATE; BROMOCRYPTINE MESYLATE METHANESULFONATE SALT; Methansulfonsäure--(6aR,9R)-5-brom-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]chinolin-9-carboxamid(1:1); (+)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)-ERGOTAMAN-3',6',18-TRIONE METHANESULFONATE; Baen; Bromocryptine mesylate; Ergotaman, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxo-, (5'α)-, methanesulfonate (1:1) (salt); (+)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6'-18-trione methanesulfonate salt; BROMOCRIPTINE METHANESULPHONATE; Ergotaman-3,6,18-trione, 2-bromo-12-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-, (5.alpha.)-, monomethanesulfonate (salt); Bromocriptine mesylate salt; 2-bromo-alpha-ergocryptinemesylate; 2-bromo-A-ergocryptine methanesulfonate salt; 2-bromo-alpha-ergokryptine-mesilate; Serono-Baen; 2-BROMOERGOCRYPTINE MONOMETHANESULFONATE SALT; (6,9R)-5-broMo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-Methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-cboxaMide Methanesulfonate; 2-BROMO-ALPHA-ERGOCRYPTINE METHANESULFONATE; Bromocriptine Mesylate (CB-154); Abmole M2472-200mg Bromocriptine Mesylate 22-1; Bromocriptine-13C-d3 Mesylate; 2-Bromo α-Ergocryptine Mesylate; 2-Bromo-12'-hydroxy-5'a-isobutyl-2'-isopropylergotaman-3',6',18-trione Monomethanesulphonate; Bromocriptine mesylate, 10 mM in DMSO; Bromocriptine mesilate CRS; Methansulfonsäure--(6aR,9R)-5-brom-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-3,6-dioxooctahydro-8H-[1,3]oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexa; MFCD00069218; bromocryptinemethanesulfonate

物化性质

• 沸点: 891.3ºC at 760 mmHg
• 分子式: C₃₃H₄₄BrN₅O₈S
• 分子量: 750.700
• 闪点: 492.8ºC
• 精确质量: 749.209412
• PSA: 180.96000
• LogP: 3.98220
• 外观性状: 白色固体
• 蒸汽压: 0mmHg at 25°C
• 储存条件:

  2-8℃

• 稳定性:

  常温常压下稳定

  避免接触 强氧化剂
• 水溶解性: H2O: 0.8 mg/mL
• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:4

  3.氢键受体数量:9

  4.可旋转化学键数量:5

  5.互变异构体数量:8

  6.拓扑分子极性表面积181

  7.重原子数量:48

  8.表面电荷:0

  9.复杂度:1320

  10.同位素原子数量:0

  11.确定原子立构中心数量:6

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:2

• 更多:

  1.性状：白色固体

  2.密度（g/mL,25/4℃）：未确定

  3.相对蒸汽密度（g/mL,空气=1）：未确定

  4.熔点（ºC）：未确定

  5.沸点（ºC,常压）：未确定

  6.沸点（ºC,5.2kPa）：未确定

  7.折射率：未确定

  8.闪点（ºC）：未确定

  9.比旋光度（º）：未确定

  10.自燃点或引燃温度（ºC）：未确定

  11.蒸气压（kPa,25ºC）：未确定

  12.饱和蒸气压（kPa,60ºC）：未确定

  13.燃烧热（KJ/mol）：未确定

  14.临界温度（ºC）：未确定

  15.临界压力（KPa）：未确定

  16.油水（辛醇/水）分配系数的对数值：未确定

  17.爆炸上限（%,V/V）：未确定

  18.爆炸下限（%,V/V）：未确定

  19.溶解性：溶于水

生物活性

• 描述: Bromocriptine mesylate 是一种有效的多巴胺 D2/D3 受体激动剂,结合多巴胺 D2 受体,pKi 为 8.05±0.2。
• 相关类别:
  信号通路 >> 自噬 >> 自噬
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 多巴胺受体
  信号通路 >> 神经信号通路 >> 多巴胺受体
  研究领域 >> 神经疾病
  天然产物 >> 其他
• 靶点:

  pKi: 8.05±0.2 (dopamine D2 receptor)[1]

• 体外研究: Bromocriptine刺激[35S]-GTPγS与CHO细胞中表达的D2多巴胺受体结合,pEC50为8.15±0.05 [1]。 Bromocriptine也是脑一氧化氮合酶的强抑制剂。麦角生物碱Bromocriptine(BKT)被发现作为纯化的神经元型一氧化氮合酶(NOS)的强抑制剂(IC50 = 10±2μM),而它对诱导型巨噬细胞NOS(IC50>100μM)的活性很差[2] 。发现溴隐亭抑制至少一种人细胞色素P450酶的活性。 Bromocriptine是一种有效的CYP3A4抑制剂,计算出的相互作用IC50值为1.69μM[3]。
• 体内研究: 在强迫游泳试验(FST)和尾部悬吊试验(TST)中,在小鼠组中给予甲磺酸布洛霉素(2mg/kg,ip)7天。与对照相比,Bromocriptine组显示出显着的抗不动作用。当在最后一次7天MPE处理后30分钟给予溴隐亭并进行FST时,与单独的MPE处理相比,该多巴胺能激动剂产生MPE(200mg/kg,口服)的抗不动作用的显着和剂量依赖性增强。与对照相比,Bromocriptine治疗组显示出不动时间的显着减少。用MPE(100和200mg/kg,po)预处理7天后给予溴隐亭,与单独的MPE治疗相比,显示出MPE的抗不动作用的显着和剂量依赖性增强[4]。与假手术(注射盐水的大鼠)相比,脑室内给予溴隐亭显着降低静态机械异常性疼痛(SMA)评分,并且其效果持续30分钟。与假手术相比,腹膜内给予溴隐亭诱导CCI-IoN组疼痛评分显着,剂量依赖性(0.1 mg和1 mg/kg)降低,其效果持续6 h。最高剂量诱导评分降低最高(P <0.01)。 Bromocriptine效应持续20分钟。与假手术相比,腹膜内施用溴隐亭诱导CCI-IoN + 6-OHDA损伤组中SMA评分的显着剂量依赖性降低。它的效果持续6小时[5]。
• 激酶实验: 进行[35S]-GTPγS结合测定。将细胞膜（25±75μg）在含有0.1mM二硫苏糖醇（DTT）和1μMGDP的缓冲液B和体积为0.9mL的药物中于30℃温育30分钟。当加入[35S]-GTPγS（50±150pM，最终浓度）（在100uL缓冲液B中）以引发反应时，该预温育确保测试的激动剂处于平衡状态。除非另有说明，否则将测定混合物再温育20分钟。通过快速过滤终止测定，并如上文对放射配体结合测定所述测定结合的放射活性。 [35S]-GTPγS的总结合小于添加[1]的20％。
• 动物实验: 小鼠[4]使用任一性别的瑞士小鼠（20-25g）（总共150只）。 Bromocriptine mesylate用作多巴胺受体（D2）激动剂。氟哌啶醇在蒸馏水中稀释，蒸馏水用于注射载体。将甲磺酸布洛霉素溶于一滴冰醋酸中，并在蒸馏水中定容。将丙咪嗪溶于0.9％生理盐水中。在强迫游泳试验（FST）和尾部悬浮试验（TST）中，在小鼠组中施用氟哌啶醇（0.1mg / kg，ip）和布洛霉素甲磺酸盐（2mg / kg，ip）7天。作为标准的丙咪嗪（10mg / kg，口服）在阳性对照组中施用7天。大鼠[5]使用成年雄性Sprague-Dawley大鼠（N = 112,275-325g）。注射6-OHDA两周后，使用面罩将动物短暂（<3分钟）用2％氟烷麻醉，并接受脑池内给药Bromocriptine（溶于5μL载体中的7μg/ kg）或单独的载体（5μL） 0.9％盐水）。对于ip注射，我们使用Bromocriptine（1mg / kg）和SKF81297（3mg / kg溶于0.9％盐水中）浓度。在恢复期（<2分钟）后，将大鼠置于观察区域中40分钟，由盲实验者进行测试。
• 参考文献:

  [1]. Gardner B, et al. Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol. 1998 Jul;124(5):978-84.

  [2]. Renodon A, et al. Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects.FEBS Lett. 1997 Apr 7;406(1-2):33-6.

  [3]. Wynalda MA, et al. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997 Oct;25(10):1211-4.

  [4]. Rana DG, et al. Dopamine mediated antidepressant effect of Mucuna pruriens seeds in various experimental models of depression. Ayu. 2014 Jan;35(1):90-7.

  [5]. Dieb W, et al. Nigrostriatal dopaminergic depletion increases static orofacial allodynia. J Headache Pain. 2016;17:11.

毒性和生态

毒理学数据: 生态学数据: CHEMICAL IDENTIFICATION RTECS NUMBER : KE1595000 CHEMICAL NAME : alpha-Ergocryptine, 2-bromo-, methanesulfonate CAS REGISTRY NUMBER : 22260-51-1 LAST UPDATED : 199504 DATA ITEMS CITED : 24 MOLECULAR FORMULA : C32-H4O-Br-N5-O5.C-H4-O3-S MOLECULAR WEIGHT : 714.43 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 50 ug/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - effect, not otherwise specified REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 340,1410,1992 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 650 ug/kg/9D-I TOXIC EFFECTS : Behavioral - hallucinations, distorted perceptions Behavioral - headache Cardiac - cardiomyopathy including infarction REFERENCE : AIMEAS Annals of Internal Medicine. (American College of Physicians, 4200 Pine St., Philadelphia, PA 19104) V.1- 1927- Volume(issue)/page/year: 118,199,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - child DOSE/DURATION : 375 ug/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Cardiac - pulse rate increase, without fall in BP Lungs, Thorax, or Respiration - respiratory stimulation REFERENCE : JOPDAB Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1932- Volume(issue)/page/year: 105,838,1984 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 1 mg/kg/20D-I TOXIC EFFECTS : Behavioral - toxic psychosis REFERENCE : AJPSAO American Journal of Psychiatry. (American Psychiatric Assoc., Circulation Dept., 1400 K St., NW, Washington, DC 20005) V.78- 1921- Volume(issue)/page/year: 143,935,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 52 mg/kg/35W-I TOXIC EFFECTS : Brain and Coverings - changes in cerebral spinal fluid REFERENCE : NEURAI Neurology. (Modern Medicine Pub., Inc., 1 E. First St., Duluth, MN 55802) V.1- 1951- Volume(issue)/page/year: 35,1193,1985 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >2 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 30,809,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >1 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 30,809,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 10500 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 29,1231,1978 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2502 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 30,809,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 189 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 30,809,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : >1 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 30,809,1979 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 8200 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 10,232,1979 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1400 mg/kg SEX/DURATION : lactating female 1-14 day(s) post-birth TOXIC EFFECTS : Reproductive - Maternal Effects - postpartum REFERENCE : JRPMAP Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969- Volume(issue)/page/year: 33,630,1988 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 42 mg/kg SEX/DURATION : female 1-7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) REFERENCE : EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945- Volume(issue)/page/year: 30,1358,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 60 mg/kg SEX/DURATION : female 6 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Maternal Effects - other effects REFERENCE : BIREBV Biology of Reproduction. (Soc. for the Study of Reproduction, 309 W. Clark St., Champaign, IL 61820) V.1- 1969- Volume(issue)/page/year: 34,788,1986 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 3 mg/kg SEX/DURATION : male 15 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct REFERENCE : IJANDP International Journal of Andrology. (Scriptor Publisher ApS, 15 Gasvaerksvej, DK-1656 Copenhagen V, Denmark) V.1- 1978- Volume(issue)/page/year: 5,331,1982 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 10500 ug/kg SEX/DURATION : female 1-7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) REFERENCE : EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945- Volume(issue)/page/year: 30,1358,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 225 ug/kg SEX/DURATION : female 3 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) REFERENCE : EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945- Volume(issue)/page/year: 24,1130,1968 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 10500 ug/kg SEX/DURATION : female 6-8 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - postpartum REFERENCE : EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945- Volume(issue)/page/year: 24,1130,1968 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 2 mg/kg SEX/DURATION : female 5 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - abortion REFERENCE : TOLED5 Toxicology Letters. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1977- Volume(issue)/page/year: 50,189,1990 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 35 mg/kg SEX/DURATION : female 14-20 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - other effects to embryo REFERENCE : GCENA5 General and Comparative Endocrinology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1961- Volume(issue)/page/year: 39,118,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 20 mg/kg SEX/DURATION : male 10 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands Reproductive - Paternal Effects - other effects on male REFERENCE : IJEBA6 Indian Journal of Experimental Biology. (Publications & Information Directorate, CSIR, Hillside Rd., New Delhi 110 012, India) V.1- 1963- Volume(issue)/page/year: 23,679,1985 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 3 mg/kg SEX/DURATION : lactating female 3 day(s) post-birth TOXIC EFFECTS : Reproductive - Maternal Effects - postpartum REFERENCE : ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,51,1976 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4920 No. of Facilities: 27 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 499 (estimated) No. of Female Employees: 225 (estimated)

安全

• 符号: GHS07, GHS09
• 信号词: Warning
• 危害声明: H302-H410
• 警示性声明: P301 + P312 + P330
• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危害码 (欧洲): Xn: Harmful;
• 风险声明 (欧洲): R20/21/22
• 安全声明 (欧洲): S22-S24/25
• 危险品运输编码: UN 3077 9 / PGIII
• WGK德国: 3
• RTECS号: KE1595000

制备